Effect of Ezetimibe on Insulin Sensitivity and Lipid Profile in Obese and Dyslipidaemic Patients
- 22 April 2006
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 20 (2) , 143-146
Abstract
Aim: To evaluate the effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 12 obese, dyslipidaemic patients, independently of their basal insulin sensitivity. At the beginning of the study, a metabolic profile was measured, and insulin sensitivity estimated using the euglycaemic-hyperinsulinaemic clamp technique. The volunteers were randomly assigned to receive ezetimibe (10 mg/day in the morning) or placebo for a period of 90 days. After intervention, a similar metabolic profile was measured and a second clamp study was performed. Results: Ezetimibe administration for 90 days decreased total (6.0 ± 0.5 vs. 4.2 ± 0.9 mmol/L, p = 0.011) and low-density lipoprotein (4.0 ± 0.7 vs. 2.2 ± 0.8 mmol/L, p=0.003) cholesterol concentrations without modification of insulin sensitivity (3.0 ± 0.6 vs. 2.9 ± 0.7 mg/kg/min, p = 0.345). Conclusions: Ezetimibe significantly decreased total cholesterol and low-density lipoprotein cholesterol concentrations without affecting insulin sensitivity in obese and dyslipidaemic patients.Keywords
This publication has 25 references indexed in Scilit:
- Adipocyte-Specific Overexpression of FOXC2 Prevents Diet-Induced Increases in Intramuscular Fatty Acyl CoA and Insulin ResistanceDiabetes, 2005
- EzetimibeClinical Pharmacokinetics, 2005
- Lipids and Glucose in Type 2 DiabetesDiabetes Care, 2004
- Sustained Reduction in Plasma Free Fatty Acid Concentration Improves Insulin Action without Altering Plasma Adipocytokine Levels in Subjects with Strong Family History of Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Ezetimibe for Management of HypercholesterolemiaAnnals of Pharmacotherapy, 2003
- Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemiaThe American Journal of Cardiology, 2002
- Obesity, free fatty acids, and insulin resistanceCurrent Opinion in Endocrinology, Diabetes and Obesity, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Skeletal Muscle TriglycerideDiabetes Care, 2001
- Glucose clamp technique: a method for quantifying insulin secretion and resistance.American Journal of Physiology-Endocrinology and Metabolism, 1979